EYPT
EyePoint Pharmaceuticals, Inc.
6.33
USD
This page is just a preview of the data found in TrendSpider’s full version
EyePoint Pharmaceuticals, Inc. stock is up 5.15% since 30 days ago. The next earnings date is Feb 29, 2024. The company has had above-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 56.25% of the previous 15 November’s closed higher than October. In the last 10 Unusual Options Trades, there were 3 CALLs, 7 PUTs. 100% of analysts rate it a buy.
| Date & Time | Expiration Date | Strike Price | Trade Type | Size | Open Interest |
|---|---|---|---|---|---|
| 11 Oct 17:42 | 19 Jan, 2024 | 15.00 | 1529 | ||
| 17 Oct 15:27 | 19 Jan, 2024 | 7.50 | 9447 | ||
| 19 Oct 14:22 | 19 Jan, 2024 | 7.50 | 125 | ||
| 27 Oct 15:39 | 19 Jan, 2024 | 5.00 | 2061 | ||
| 13 Nov 17:32 | 17 Nov, 2023 | 10.00 | 71 | ||
| 20 Nov 17:20 | 19 Jan, 2024 | 2.50 | 24 | ||
| 24 Nov 14:58 | 19 Jan, 2024 | 5.00 | 3730 | ||
| 24 Nov 15:34 | 19 Jan, 2024 | 5.00 | 3730 | ||
| 27 Nov 20:45 | 19 Jan, 2024 | 7.50 | 9623 | ||
| 29 Nov 17:35 | 19 Jan, 2024 | 7.50 | 9739 |
EyePoint Pharmaceuticals, Inc. provides ILUVIEN, an injectable sustained-release micro-insert for treatment of diabetic macular edema. DEXYCU, a dexamethasone intraocular suspension, for the treatment of post-operative ocular inflammation, including treatment following cataract surgery. It is also developing EYP-1901, a twice-yearly bioerodible formulation of tyrosine kinase inhibitor for the. treatment of wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion.
